Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becoming increasingly fragmented as more biomarker-driven therapies enter the market. Nevertheless, owing to the limited size of these patient subpopulations, the immune checkpoint inhibitors, most notably Keytruda (Merck & Co.), continue to dominate the NSCLC market. Competition is set to intensify further over the forecast period as multiple immune checkpoint inhibitor-based combination therapies gain approval and enter clinical practice. In addition, a flurry of novel agents and regimens from different drug classes are in development for NSCLC, including ALK, MET, and RET inhibitors, immune checkpoint inhibitors, angiogenesis inhibitors, and therapeutic vaccines, all vying for a share of the increasingly crowded and competitive market.

Questions Answered

  • How are the drug-treatable populations defined in NSCLC? How do these differ in size, and will drug-treatment rates per population change over time?
  • How will recent and expected market approvals shape the treatment landscape in first-line metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative setting?
  • What pipeline products are considered most promising, and what uptake and patient share could they secure in NSCLC? What key therapies are in earlier phases of development?
  • What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 16 interviews with experts and country-specific surveys with medical oncologists (~30 per country) who treat NSCLC.

Epidemiology: Diagnosed and recurrent incidence of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.

Population segments in market forecast: Stage IB/II, stage III, first-line, second-line, and third-line for metastatic adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.

Emerging therapies: Phase III/PR: 19 drugs; coverage of select agents in Phase II and Phase I development.

Table of contents

  • Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Key Updates
          • January 2021
          • December 2020
          • September 2020
          • May 2020
          • December 2019
          • September 2019
        • Market Outlook
          • Key Findings
            • Major-Market Share of Drug Classes for NSCLC: 2019
            • Major-Market Share of Drug Classes for NSCLC: 2029
            • Key Current Therapies in NSCLC: Population Positioning
            • Emerging Therapies in NSCLC: Population Positioning
            • NSCLC SWOT Analysis
          • COVID-19: Areas of Potential Forecast Impact
            • Market Drivers and Constraints
              • What Factors Are Driving the Market for NSCLC?
              • What Factors Are Constraining the Market for NSCLC?
              • Drug-Treatable Population Share and Major-Market Sales Share in NSCLC: 2019
              • Drug-Treatable Population Share and Major-Market Sales Share in NSCLC: 2029
              • Major-Market Sales of Key Therapies for NSCLC (Excluding Immune Checkpoint Inhibitors): 2019-2029
              • Major-Market Sales of Immune Checkpoint Inhibitors for NSCLC: 2019-2029
              • Major-Market Share of Immune Checkpoint Inhibitors in NSCLC, by Patient Population (All Histologies): 2029
            • Segment-Specific Trends
              • Patient-Share Dynamics of Key Regimens in First-Line Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • Patient-Share Dynamics of Key Regimens in First-Line Metastatic NSCLC (Squamous), United States: 2019-2029
              • Patient-Share Dynamics of Key Therapies in First-Line EGFR-Positive Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • ALK Inhibitors
              • Patient-Share Dynamics of Key Therapies in First-Line ALK-Positive Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • Patient-Share Dynamics of Immune Checkpoint Inhibitors (Without Chemotherapy) in First-Line Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • Patient-Share Dynamics of Immune Checkpoint Inhibitors (With Chemotherapy) in First-Line Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • Patient-Share Dynamics of Key Regimens in Second-Line Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • Patient-Share Dynamics of Key Regimens in Second-Line Metastatic NSCLC (Squamous), United States: 2019-2029
              • Patient-Share Dynamics of Immune Checkpoint Inhibitors in Second-Line Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • Patient-Share Dynamics of Immune Checkpoint Inhibitors in Second-Line Metastatic NSCLC (Squamous), United States: 2019-2029
              • Patient-Share Dynamics of Immune Checkpoint Inhibitors in Third-Line Metastatic NSCLC (Adenocarcinoma), United States: 2019-2029
              • Patient-Share Dynamics of Immune Checkpoint Inhibitors in Third-Line Metastatic NSCLC (Squamous), United States: 2019-2029
          • Forecast
            • Market Forecast Assumptions
            • Market Forecast Dashboard
          • Etiology and Pathophysiology
            • Disease Overview
              • Disease Pathophysiology
                • Progression of NSCLC
                • Anatomy and Histology of NSCLC
                • Natural History of NSCLC
                • Timing of Genetic Changes in NSCLC
              • Staging and Classification
                • Classification of NSCLC
                • Staging of NSCLC
                • Descriptors for Tumor, Node, and Metastasis Stages for NSCLC
                • Definitions of the TNM Staging System for NSCLC
              • Key Pathways and Drug Targets
                • Key Pathways and Drug Targets for NSCLC
            • Epidemiology
              • Key Findings
                • Epidemiology Populations
                  • Disease Definition
                  • Methods
                  • Sources Used for Diagnosed Incidence of NSCLC
                  • Number of Diagnosed Incident Cases of NSCLC in the Major Pharmaceutical Markets by Histology: 2019-2029
                  • Disease Definition
                  • Methods
                  • Sources Used for Stage Distribution of NSCLC
                  • Number of Diagnosed Incident Cases of Adenocarcinoma in the Major Pharmaceutical Markets by Stage at Diagnosis: 2019-2029
                  • Number of Diagnosed Incident Cases of Squamous Cell Carcinoma in the Major Pharmaceutical Markets by Stage at Diagnosis: 2019-2029
                  • Number of Diagnosed Incident Cases of Large-Cell and Other in the Major Pharmaceutical Markets by Stage at Diagnosis: 2019-2029
                  • Number of Diagnosed Incident Cases of Unverified NSCLC in the Major Pharmaceutical Markets by Stage at Diagnosis: 2019-2029
                  • Disease Definition
                  • Methods
                  • Sources Used for Recurrent Incident Cases of NSCLC
                  • Number of Recurrent Incident Cases of NSCLC in the Major Pharmaceutical Markets by Histology: 2019-2029
                  • Non-Small-Cell Lung Cancer Patient Flow
                  • Drug-Treatable Cases of Adenocarcinoma NSCLC: 2019-2029
                  • Drug-Treatable Cases of Large-Cell, Other, and Unverified NSCLC: 2019-2029
                  • Drug-Treatable Cases of Squamous Cell NSCLC: 2019-2029
                  • Drug-Treated Cases of Adenocarcinoma NSCLC: 2019-2029
                  • Drug-Treated Cases of Large-Cell, Other, and Unverified NSCLC: 2019-2029
                  • Drug-Treated Cases of Squamous Cell NSCLC: 2019-2029
              • Current Treatment
                • Key Findings
                  • Treatment Goals
                    • Key Endpoints Used in Clinical Trials for Non-Small-Cell Lung Cancer
                  • Key Current Therapies
                    • Overview
                    • Mechanism of Action of Key Current Drug Classes Used for Non-Small-Cell Lung Cancer
                    • Current Treatments Used for Non-Small-Cell Lung Cancer
                    • Market Events Impacting the Use of Key Current Therapies in Non-Small-Cell Lung Cancer
                    • Key Results from Select Clinical Trials Investigating Tagrisso for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Tagrisso
                    • Key Ongoing Clinical Trials of Tagrisso in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Tagrisso
                    • Advantages and Disadvantages of Tarceva
                    • Ongoing Clinical Development Tarceva
                    • Key Ongoing Clinical Trials of Tarceva in the Treatment of Non-Small-Cell Lung Cancer
                    • Advantages and Disadvantages of Iressa
                    • Advantages and Disadvantages of Gilotrif/Giotrif
                    • Key Results from Select Clinical Trials Investigating Vizimpro for the Treatment of NSCLC
                    • Advantages and Disadvantages of Portrazza
                    • Advantages and Disadvantages of Xalkori
                    • Ongoing Clinical Development of Xalkori
                    • Key Ongoing Clinical Trials of Xalkori in the Treatment of Non-Small-Cell Lung Cancer
                    • Advantages and Disadvantages of Zykadia
                    • Ongoing Clinical Development of Zykadia
                    • Expert Insight: Zykadia
                    • Key Results from Select Clinical Trials Investigating Alecensa for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Alecensa
                    • Key Ongoing Clinical Trials of Alecensa in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Alecensa
                    • Key Results from Select Clinical Trials Investigating Alunbrig for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Alunbrig
                    • Key Ongoing Clinical Trials of Alunbrig for the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Alunbrig
                    • Key Results from Select Clinical Trials Investigating Lorbrena for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Lorbrena
                    • Key Ongoing Trials of Lorbrena in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Lorbrena/Lorviqua
                    • Key Results from Select Clinical Trials Investigating Tabrecta for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Tabrecta
                    • Key Ongoing Clinical Trials of Tabrecta in the Treatment of Non-Small-Cell Lung Cancer
                    • Key Results from Select Clinical Trials Investigating Tepmetko for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Tepmetko
                    • Key Ongoing Clinical Trials of Tepmetko in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: MET Inhibitors for Non-Small-Cell Lung Cancer
                    • Key Results from Select Clinical Trials Investigating Retevmo for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Retevmo
                    • Key Ongoing Clinical Trials of Retevmo in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insights: Retevmo
                    • Gavreto
                    • Key Results from Select Clinical Trials Investigating Gavreto for the Treatment of NSCLC
                    • Ongoing Clinical Development of Gavreto
                    • Key Ongoing Clinical Trials of Gavreto in the Treatment of NSCLC
                    • Key Results from Select Clinical Trials Investigating Rozlytrek for the Treatment of NSCLC
                    • Ongoing Clinical Development of Rozlytrek
                    • Key Ongoing Clinical Trials of Rozlytrek in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Rozlytrek
                    • Advantages and Disadvantages of Tafinlar and Mekinist Combination Therapy
                    • Ongoing Clinical Development of Tafinlar and Mekinist Combination Therapy
                    • Expert Insight: Tafinlar and Mekinist
                    • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Keytruda
                    • Key Ongoing Clinical Trials of Keytruda in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Keytruda
                    • Opdivo
                    • Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Opdivo
                    • Key Ongoing Clinical Trials of Opdivo in the Treatment of Non-Small-Cell Lung Cancer
                    • Opdivo Combination Therapies
                    • Key Results from Select Clinical Trials Investigating Opdivo Combination Therapies for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Opdivo Combination Therapies
                    • Key Ongoing Clinical Trials of Opdivo Combination Therapies in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Opdivo and Yervoy Combination Therapy
                    • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Tecentriq
                    • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Tecentriq
                    • Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of Non-Small-Cell Lung Cancer
                    • Ongoing Clinical Development of Imfinzi
                    • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Non-Small-Cell Lung Cancer
                    • Expert Insight: Imfinzi
                    • Advantages and Disadvantages of Avastin
                    • Ongoing Clinical Development of Avastin
                    • Select Phase III Trials Investigating Avastin in the Treatment of Non-Small-Cell Lung Cancer
                    • Key Results from Select Clinical Trials Investigating Cyramza for the Treatment of NSCLC
                    • Ongoing Clinical Development of Cyramza
                    • Expert Insight: Cyramza
                    • Advantages and Disadvantages of Vargatef
                    • Advantages and Disadvantages of Alimta
                    • Advantages and Disadvantages of Abraxane
                    • Ongoing Clinical Development of Abraxane
                  • Medical Practice
                    • Localized Stage I/II and Resectable and Unresectable Stage III Non-Small-Cell Lung Cancer
                    • First-Line Metastatic Nonsquamous Non-Small-Cell Lung Cancer
                    • First-Line Metastatic Squamous Non-Small-Cell Lung Cancer
                    • Second- and Third-Line Metastatic Nonsquamous Non-Small-Cell Lung Cancer
                    • Second- and Third-Line Metastatic Squamous Non-Small-Cell Lung Cancer
                    • Treatment Guidelines
                    • Country-Specific or Regional Non-Small-Cell Lung Cancer Treatment Guidelines
                    • Patient Characteristics Influencing Drug Selection
                    • Treatment Decision Tree for Localized (Stage I/II) Non-Small-Cell Lung Cancer
                    • Treatment Decision Tree for Locally Advanced (Stage III) Non-Small-Cell Lung Cancer
                    • Treatment Decision Tree for Metastatic (Stage IV) Nonsquamous Non-Small-Cell Lung Cancer
                    • Treatment Decision Tree for BRAF-Mutation and ROS-1-Positive Metastatic (Stage IV) Nonsquamous Non-Small-Cell Lung Cancer
                    • Treatment Decision Tree for RET-Mutant and MET-Mutant Metastatic (Stage IV) Nonsquamous Non-Small-Cell Lung Cancer
                    • Treatment Decision Tree for Metastatic (Stage IV) Squamous Non-Small-Cell Lung Cancer
                • Unmet Need Overview
                  • Current and Future Attainment of Unmet Needs in NSCLC
                  • Top Unmet Needs in NSCLC: Current and Future Attainment
                • Emerging Therapies
                  • Key Findings
                    • Pipeline Trends in NSCLC
                  • Key Emerging Therapies
                    • Key Therapies in Development for NSCLC
                    • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of NSCLC
                    • Key Results from Select Clinical Trials Investigating Mobocertinib for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Mobocertinib for the Treatment of NSCLC
                    • Analysis of Clinical Development Program for Mobocertinib
                    • Expectations for Market Authorization and Sales Opportunity of Mobocertinib in NSCLC
                    • Expert Insight: Mobocertinib
                    • Key Results from Select Clinical Trials Investigating Lazertinib for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Lazertinib in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Lazertinib
                    • Expectations for Market Authorization and Sales Opportunity of Lazertinib in NSCLC
                    • Key Results from Select Clinical Trials Investigating Ensartinib for the Treatment of NSCLC
                    • Key Ongoing Trials of Ensartinib in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Ensartinib
                    • Expectations for Market Authorization and Sales Opportunity of Ensartinib in NSCLC
                    • Key Results from Select Clinical Trials Investigating Sotorasib for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Sotorasib in the Treatment of NSCLC
                    • Analysis of Clinical Development Program for Sotorasib
                    • Expectations for Market Authorization and Sales Opportunity of Sotorasib in NSCLC
                    • Expert Insight: Sotorasib
                    • Key Results from Select Clinical Trials Investigating Adagrasib for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Adagrasib in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Adagrasib
                    • Expectations for Market Authorization and Sales Opportunity of Adagrasib in NSCLC
                    • Key Results from Select Clinical Trials Investigating Bavencio for the Treatment of NSCLC
                    • Key Ongoing Trials of Bavencio in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Bavencio
                    • Expert Insight: Use of Bavencio in the Treatment of NSCLC
                    • Expectations for Launch and Sales Opportunity of Bavencio in NSCLC
                    • Key Results from Select Clinical Trials Investigating Tremelimumab for the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Tremelimumab
                    • Expert Insight: Use of Tremelimumab in the Treatment of NSCLC
                    • Expectations for Launch and Sales Opportunity of Tremelimumab in NSCLC
                    • Key Results from Select Clinical Trials Investigating Libtayo for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Libtayo in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Libtayo
                    • Expectations for Launch and Sales Opportunity of Libtayo in NSCLC
                    • Key Results from Select Clinical Trials Investigating Tislelizumab for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Tislelizumab in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Tislelizumab
                    • Expectations for Market Authorization and Sales Opportunity of Tislelizumab in NSCLC
                    • Key Ongoing Clinical Trials of Retifanlimab for the Treatment of NSCLC
                    • Analysis of Clinical Development Program for Retifanlimab
                    • Expectations for Market Authorization and Sales Opportunity of Retifanlimab in NSCLC
                    • Key Results from Select Clinical Trials Investigating Tiragolumab for the Treatment of NSCLC
                    • Analysis of Clinical Development Program for Tiragolumab
                    • Key Ongoing Clinical Trials of Tiragolumab for the Treatment of NSCLC
                    • Expectations for Market Authorization and Sales Opportunity of Tiragolumab in NSCLC
                    • Key Results from Select Clinical Trials Investigating Bintrafusp Alfa for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Bintrafusp Alfa in the Treatment of NSCLC
                    • Analysis of Clinical Development Program for Bintrafusp Alfa
                    • Expectations for Market Authorization and Sales Opportunity of Bintrafusp Alfa in NSCLC
                    • Key Results from Select Clinical Trials Investigating Amivantamab for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Amivantamab in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Amivantamab
                    • Expectations for Market Authorization and Sales Opportunity of Amivantamab in NSCLC
                    • Key Results from Select Clinical Trials Investigating Lenvima for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Lenvima in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Lenvima
                    • Expectations for Market Authorization and Sales Opportunity of Lenvima in NSCLC
                    • Key Results from Select Clinical Trials Investigating Cabometyx for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Cabometyx in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Cabometyx
                    • Expectations for Market Authorization and Sales Opportunity of Cabometyx in NSCLC
                    • Key Results from Select Clinical Trials Investigating Sitravatinib for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Sitravatinib in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Sitravatinib
                    • Expectations for Market Authorization and Sales Opportunity of Sitravatinib in NSCLC
                    • Key Results from Select Clinical Trials Investigating Plinabulin for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Plinabulin in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Plinabulin
                    • Expert Insight: Use of Plinabulin in the Treatment of NSCLC
                    • Expectations for Launch and Sales Opportunity of Plinabulin in NSCLC
                    • Key Ongoing Clinical Trials of Lynparza in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Lynparza
                    • Expert Insight: Lynparza
                    • Expectations for Market Authorization and Sales Opportunity of Lynparza in NSCLC
                    • Key Results from Select Clinical Trials Investigating Zejula for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Zejula in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Zejula
                    • Expectations for Market Authorization and Sales Opportunity of Zejula in NSCLC
                    • Key Results from Select Clinical Trials Investigating OSE-2101 for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of OSE-2101 in the Treatment of NSCLC
                    • OSE-2101 Clinical Development
                    • Expert Insight: Use of OSE-2101 in the Treatment of NSCLC
                    • Expectations for Launch and Sales Opportunity of OSE-2101 in NSCLC
                    • Key Results from Select Clinical Trials Investigating Canakinumab for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Canakinumab in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Canakinumab
                    • Expert Insight: Canakinumab
                    • Expectations for Market Authorization and Sales Opportunity of Canakinumab in NSCLC
                    • Key Results from Select Clinical Trials Investigating SAR408701 for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of SAR408701 in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for SAR408701
                    • Expectations for Market Authorization and Sales Opportunity of SAR408701 in NSCLC
                    • Key Results from Select Clinical Trials Investigating Datopotamab deruxtecan for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Datopotamab deruxtecan in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Datopotamab deruxtecan
                    • Expectations for Market Authorization and Sales Opportunity of Datopotamab deruxtecan in NSCLC
                    • Key Results from Select Clinical Trials Investigating Pyrotinib for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Pyrotinib in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Pyrotinib
                    • Expectations for Market Authorization and Sales Opportunity of Pyrotinib in NSCLC
                    • Key Results from Select Clinical Trials Investigating VS-6766 for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of VS-6766 in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for VS-6766
                    • Expectations for Market Authorization and Sales Opportunity of VS-6766 in NSCLC
                    • Key Results from Select Clinical Trials Investigating Defactinib for the Treatment of NSCLC
                    • Key Ongoing Clinical Trials of Defactinib in the Treatment of NSCLC
                    • Analysis of the Clinical Development Program for Defactinib
                    • Expectations for Market Authorization and Sales Opportunity of VS-6766 in NSCLC
                  • Early-Phase Pipeline Analysis
                    • Select Compounds in Phase II Development for NSCLC
                • Access and Reimbursement Overview
                  • Region-Specific Reimbursement Practices
                    • Key Market Access Considerations in NSCLC: United States
                    • General Reimbursement Environment: United States
                    • Key Market Access Considerations in NSCLC: EU5
                    • General Reimbursement Environment: EU5
                    • Key Market Access Considerations in NSCLC: Japan
                    • General Reimbursement Environment: Japan
                  • Looking for More?
                • Appendix
                  • Key Abbreviations Related to NSCLC
                  • Brands, Marketers, and Generic Availability of Current Therapies Used for NSCLC, by Market
                  • NSCLC Bibliography

              Author(s): Arman Esfandiari, Ph.D.; Atul Sharma, M.P.H.

              Arman Esfandiari, M.Res., Ph.D., is an analyst on the Oncology and Biosimilars teams at DRG, part of Clarivate. He has a long-standing interest in cancer therapeutics and holds a Ph.D. in cancer biology from Newcastle University. As a postdoctoral research fellow at the Northern Institute for Cancer Research and at University College London, he focused on the research and development of small-molecule inhibitors, DNA-damaging agents, and antibody-drug conjugates. 

              Atul Sharma, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. He holds a master’s degree in public health from the School of Public Health, Post-Graduate Institute of Medical Education and Research, and a bachelor’s degree in dental surgery from MN DAV Dental College and Hospital.


              Related Reports

              Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China)

              Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...

              View Details

              Non-Small-Cell Lung Cancer - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (EU5)

              This report is available to find out more click the link and fill out the form to get more details.

              View Details

              Non-Small-Cell Lung Cancer - Current Treatment - Detailed, Expanded Analysis (EU5) - 2020

              The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has r...

              View Details

              Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Squamous NSCLC (US/EU)

              The preferred initial treatment for metastatic squamous non-small-cell lung cancer (NSCLC), regardless of PD-...

              View Details